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Hypoxanthine guanine phosphoribosyltransferase (HGPRT;
enzyme classification code 2.4.2.8) converts hypoxanthine
(a precursor of uric acid) and guanine to inosine
monophosphate (IMP) and guanosine monophosphate
(GMP). Somatic cell mutation studies on the HGPRT gene
have provided important information about the genetic
effects of exogenous exposure to carcinogens in healthy
populations. These studies have also revealed much on the
disease mechanisms in individuals at increased risk of
ASSOCIATION BETWEEN CIGARETTE SMOKING
AND HYPOXANTHINE GUANINE
PHOSPHORIBOSYLTRANSFERASE ACTIVITY
Shun-Jen Chang,1 Shiu-Min Chen,2 Shang-Lun Chiang,3 Kee-Lung Chang,4 and Ying-Chin Ko3
1Department of Public Health, School of Medicine, 2Graduate Institute of Public Health,
3National Health Research Institutes, and 4Department of Biochemistry,
Kaohsiung Medical University, Kaohsiung, Taiwan.
The aim of this study was to investigate the association between smoking behavior and hypoxanthine
guanine phosphoribosyltransferase (HGPRT) activity. A cross-sectional study was performed of 82 men,
including 38 non-smokers and 44 smokers. Inosine monophosphate (IMP), the product of HGPRT (used as
the index of activity), was measured in peripheral blood mononuclear cells using high-performance liquid
chromatography. The factors potentially associated with HGPRT activity included age, glutamyl oxaloacetic
transaminase, glutamyl pyruvic transaminase, cholesterol, uric acid, triglycerides, creatinine, body mass
index, gout, systolic blood pressure, diastolic blood pressure, alcohol consumption, and cigarette smoking.
Mean HGPRT activity was 7.05 ( 3.44 nmol/106 viable cells/hour for all participants, and was significantly
lower for smokers than for non-smokers (6.24 (  3.40 vs 7.98 ( 3.28 nmol/106 viable cells/hour; p = 0.02).
In addition, as the number of smoked cigarettes increased, the HGPRT activity decreased (p < 0.05). The age
at onset of cigarette smoking showed a positive correlation with HGPRT activity after adjusting for smoking
duration, serum uric acid, and cigarettes smoked per year using a multiple regression model (p < 0.001).
We concluded that the greater the number of cigarettes smoked, the lower the HGPRT activity, and that
HGPRT activity was higher in smokers who had started smoking later.
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developing cancer and other disorders [1]. A mutation in
the HGPRT gene can cause increased hypoxanthine and
guanine levels and, thereby, increase serum uric acid salt
levels. Some HGPRT cDNA mutations have been shown to
cause Lesch-Nyhan syndrome and gout [2–8], and, even in
healthy individuals, the HGPRT mutation varies frequently
in peripheral blood T-cells [9,10]. An elevated HGPRT
mutant frequency has been confirmed in the newborns of
women smokers [11,12]. Several studies found that HGPRT
mutant frequency increases 20–100% with increased
smoking and age [9,10,13,14], but few studies have
examined the relationship between HGPRT activity and
cigarette smoking. Thus, the aim of this study was to
explore the association between HGPRT activity and
smoking behavior.
© 2005 Elsevier. All rights reserved.
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MATERIALS AND METHODS
A cross-sectional study was performed to evaluate the
association of HGPRT activity with smoking status,
demographic factors, history of gout, and living habits.
The study population was 82 men (38 non-smokers, 44
smokers). Informed consent was obtained from all
participants, who gave roughly 10 mL of blood to determine
HGPRT activity and levels of uric acid, triglycerides, total
cholesterol, glutamyl oxaloacetic transaminase (GOT),
glutamyl pyruvic transaminase (GPT), and creatinine.
Plasma was extracted from blood samples and stored at
–70$C before analysis with an autoanalyzer (Biotechnica,
Hitachi, Tokyo).
Questionnaire
We used a structured questionnaire to interview the
participants. Data on sociodemographics, body height, body
weight, blood pressure, history of gout, and history of
behaviors such as cigarette smoking and alcohol
consumption were collected from each participant.
Definition of variables
The number of cigarettes currently smoked per day, duration
of smoking, and age at onset of smoking were recorded.
Alcohol consumption was defined as consumption of 200
mL of alcoholic beverage (regardless of the beverage or its
alcohol concentration) more than four times per week. Total
cigarette or alcohol consumption was calculated from the
frequency multiplied by duration of these behaviors.
Participants were classified as either non-smokers, light
smokers (< 20 cigarettes/day), or heavy smokers (* 20
cigarettes/day) according to their current habits. Former
smokers who had quit smoking for more than 1 year were
classified as non-smokers.
HGPRT activity
The amount of IMP, measured using a high-performance
liquid chromatography (HPLC) detection system (Waters
610, Milford, MA, USA), was used to express HGPRT activity
[15].
From each participant, a total of 10 mL of venous blood
was collected in a tube coated with heparin and centrifuged
at room temperature for 10 minutes at 1,000 g. Peripheral
blood mononuclear cells (PBMCs) were collected from the
interface and washed with approximately 9 mL of red
blood cell lysis solution (170 mM Tris, 155 mM NH4Cl;
1:9, v/v; pH 7.2–7.4). About 3 mL of phosphate buffered
saline was added to wash the pellet, which was centrifuged
again at room temperature for 5 minutes at 825 g. After
this, the cell pellet was resuspended in 3 mL of RPMI
solution (with 10% fetal bovine serum). PBMCs were
stained with 0.4% trypan blue (1:1, v/v) to calculate the
percent viable cells, and a total of one million cells were
collected for further assay. Since the HGPRT enzyme
c o n v e r t s  h y p o x a n t h i n e  a n d  p h o s p h o r i b o s y l
pyrophosphate (PRPP) to IMP and inosine, the amount of
IMP increase can be used as an index of HGPRT activity.
A reaction mixture with a pH of 7.4 was prepared; it
consisted of 4 nmol/10 +L hypoxanthine (Sigma, St Louis,
MO, USA), 8 mM PRPP (Sigma), 0.5 M Tris, 0.05 M MgCl2,
and 10% Triton X-100 (10:10:10:1, v/v). After adding 20
mL of this mixture to the PBMC pellet, the combination
was allowed to synthesize IMP for 1.5 hours at 37$C. The
incubation mixture was deproteinized by addition of
30 +L of ice-old perchloric acid (0.8 M), and 15 +L of the
supernatant was neutralized with 35 +L of 0.2 M KH2PO4.
The mixture was stored at –20$C for further HPLC
separation.
HGPRT activity was measured using HPLC on the
basis of the conversion of hypoxanthine to IMP. A
Supelcosil LC-18-S column (250 = 4.6 mm inner diameter;
particle size, 5 +m), continuous mobile-phase degasser,
and ultraviolet detector with wavelength set at 254 nm
were used with a two-buffer (A [0.025 M KH2PO4] and B
[25% methanol, 75% 0.05 M KH2PO4]) gradient elution
system to separate the IMP mixture. The operating pressure
was 90 bars and the flow-rate was 1.25 mL/min. The
incubation mixture was thawed and centrifuged at room
temperature for 4 minutes at 15,000 g, and then 20 +L of the
supernatant was injected into the HPLC system.
Calculation of specific enzyme activity
The concentration of IMP was measured using a standard
curve (peak vs concentration). Four different known
concentrations of IMP standards were injected into the
HPLC system to obtain the standard curve, which had a
linear regression coefficient equal to 0.999. HGPRT activity
was calculated and expressed in nmol of IMP in one million
viable cells per hour of incubation (nmol/106 viable cells/
hour).
Statistical analysis
The Shapiro-Wilk normality test was used to assess the
distribution of the IMP concentration (HGPRT activity
index). Parametric methods were used to analyze the
association between factors related to HGPRT activity. A
simple regression method was used to test the relationships
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between uric acid (or HGPRT activity) and the investigated
factors. Confounders were adjusted using a multiple
regression model when the variables in the simple
regression showed a significant difference (p < 0.05). One-
way analysis of variance (ANOVA) was used to analyze
differences in the means among more than two categorical
variables if they were normally distributed, and a
Bonferroni approach for multiple comparisons was used
to test mean differences between subgroups. The statistics
were processed by SAS version 8.2 software (SAS Institute,
Cary, NC, USA). Test results were considered significant
if p was less than 0.05.
RESULTS
Of the 82 male participants, 26 were non-smokers, 12 former
smokers, and 44 current smokers. Of the 44 current smokers,
13 were light smokers and 31 were heavy smokers. The
mean age for all subjects was 48.9 ( 11.9 years; non-smokers
were older than light smokers or heavy smokers (Table 1;
p = 0.001).
HGPRT activity data for all participants were normally
distributed around a mean value of 7.05 (  3.44 (nmol/106
viable cells/hour). HGPRT activity differed among the
three groups (p  < 0.05; Table 1). After posterior
comparisons, mean HGPRT activity in non-smokers (7.91
( 3.26 nmol/106 viable cells/hour) was significantly higher
than that in heavy smokers (5.69 (  3.52 nmol/106 viable
cells/hour) or all smokers (6.24 (  3.40 nmol/106 viable
cells/hour; p = 0.017; Table 1).
Among the three smoking behaviors, there was no
significant difference with regard to biochemical factors
(e.g. serum uric acid, cholesterol, triglycerides, GOT, GPT,
and creatinine), blood pressure, and body mass index (BMI).
Moreover, no significant associations between these
parameters and HGPRT activity were found using simple
regression (data not shown).
Among cigarette smokers, the mean age was 45.59 (
9.02 years, the mean duration of smoking was 24.28 ( 11.19
years, and the age at onset of smoking was 20.59 (  6.69
years. The age at onset of smoking and duration of smoking
showed significant associations with HGPRT activity in the
simple regression analysis (p < 0.05), but the age and number
of cigarettes consumed per day did not. The mean uric acid
concentration was 8.37 (  2.30 mg/dL for all participants,
and had a significantly negative association with HGPRT
activity (` = –0.37, standard error [SE] = 0.16; p = 0.025; Table
2). After associations were shown between HGPRT activity
and age at onset of smoking, duration of smoking, and uric
Table 1. Analysis of the associations between various factors and current cigarette smoking behaviors
Non-smokers
Light smokers Heavy smokers
(< 20 cigarettes/day) (* 20 cigarettes/day) p
(n = 38)
(n = 13) (n = 31)
Age (yrs) 55.16 ( 14.45 41.46 ( 9.10 47.32 ( 8.55 0.001*
HGPRT activity (nmol/106 viable cells/h) 7.98 ( 3.28 7.55 ( 2.78 5.69 ( 3.52 0.017†
Uric acid (mg/dL) 8.24 ( 2.43 7.78 ( 1.82 8.78 ( 2.32 0.383
GOT (IU) 38.34 ( 18.68 43.85 ( 40.93 43.42 ( 23.49 0.645
GPT (IU) 33.13 ( 26.02 42.38 ( 28.42 37.26 ( 21.73 0.491
Cholesterol (mg/dL) 204.58 ( 50.04 208.69 ( 45.45 193.74 ( 42.24 0.516
Triglycerides (mg/dL) 250.47 ( 262.64 195.23 ( 133.49 313.29 ( 169.87 0.216
Creatinine (mg/dL) 1.35 ( 0.21 1.18 ( 0.18 1.29 ( 0.38 0.195
BMI (kg/m2) 27.19 ( 3.46 26.24 ( 4.60 27.90 ( 7.53 0.666
Systolic blood pressure (mmHg) 131.69 ( 19.02 129.64 ( 15.49 130.04 ( 23.95 0.934
Diastolic blood pressure (mmHg) 83.17 ( 11.89 82.45 ( 9.27 85.36 ( 12.09 0.690
Total alcohol consumption (g/week) 24.75 ( 27.11 63.01 ( 54.74 27.27 ( 28.85 0.004‡
*Significant difference between non-smokers and heavy smokers or light smokers; †significant difference between non-smokers and heavy
smokers; ‡significant difference between light smokers and non-smokers or heavy smokers. HGPRT = hypoxanthine guanine
phosphoribosyltransferase; GOT = glutamyl oxaloacetic transaminase; GPT = glutamyl pyruvic transaminase; BMI = body mass index.
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acid concentrations, we performed a multiple regression
analysis to explore the association between these factors
and HGPRT activity. Serum uric acid and the age at onset of
smoking were significantly associated with HGPRT activity,
with an inverse correlation for serum uric acid and a positive
correlation for age at onset of smoking (` = 0.27, SE = 0.07;
p < 0.01; Table 2).
DISCUSSION
This study explored the association between HGPRT activity
and smoking behavior. The results showed that non-smokers
had higher HGPRT activity than heavy smokers or smokers
as a whole. Some studies have shown that cigarette smoking
is correlated with increased mutant frequency [9,10,14].
Podlutsky et al also found that the HGPRT gene of smokers
had a higher frequency of transversions and a lower
frequency of transitions than the corresponding gene of
non-smokers, which suggests that cigarette smoke may
induce adducts at guanine bases in the non-transcribed
DNA strand, contributing to an increase in HGPRT gene
mutation in smokers [16]. Ammenheuser et al confirmed
that heavy smokers had higher frequencies of HGPRT
mutant variants induced by exposure to 6-thioguanine than
non-smokers or light smokers [17,18]. An increase in the
numbers of cigarettes smoked per day raises the plasma
cotinine (a metabolite of nicotine) [19]. Our study, which
demonstrated lower HGPRT activity in cigarette smokers,
combined with Ammenheuser’s results may suggest that
more frequent HGPRT mutations in smokers will cause
enzyme activity to decline, and it can be considered that
nicotine degrades HGPRT activity.
This study did not show age to be significantly
correlated with HGPRT activity, in contrast to some studies,
in which HGPRT mutant frequencies in lymphocytes
increased with age [9,10,14,20,21]. However, this study
did show that, for current smokers, an older age at onset of
cigarette smoking correlated with higher HGPRT activity
after adjusting for duration of smoking or age. Many
studies have reported that DNA hypermethylation is
associated with exposure to tobacco smoke [22–24]. Kim et
al provided evidence that starting cigarette smoking at an
early age is strongly associated with hypermethylation of
the promoter in the ras-association domain family 1A gene
[25]. The relationship between age and mutant frequency
in lymphocytes depends critically on the relationship
between age and lymphocyte biology. Many features of
the development and decline of the immune response are
known. Immunologic memory is believed to reside in the
clonal continuity of cells that have more rapid turnover
than non-memory cells [26]. These memory cells are likely
to be especially important in the reporting of mutations
induced by exposure to endogenous and exogenous
genotoxins from cigarette smoke. There is evidence that
the number of certain lymphocyte types declines in vivo
with age [27], that starting cigarette smoking at an early
age will cause genetic hypermethylation, and that HGPRT
activity correlates with the age at onset. Nevertheless, the
molecular mechanism remains elusive.
The finding that plasma uric acid level was negatively
related to HGPRT activity in this study agrees with the well-
known causal effect between serum uric acid level and
HGPRT activity [8,28–30], and suggests the measurement
of HGPRT activity is reliable. In gout patients, plasma uric
acid level was not significantly related to HGPRT activity,
Table 2. Multiple regression analysis of the associations between hypoxanthine guanine phosphoribosyltransferase (HGPRT)
activity and cigarette smoking
HGPRT activity
Mean ( SD Parameter
p1 p2(n = 44) estimated ( SE
Age (yrs) 45.59 ( 9.02 –0.01 ( 0.06 0.851 -
Age at onset of smoking (yrs) 20.59 ( 6.69 0.27 ( 0.07 0.001 0.001
Duration of smoking (yrs) 24.28 ( 11.19 –0.10 ( 0.04 0.031 0.370
Cigarettes/day 22.25 ( 15.09 –0.02 ( 0.03 0.572 -
Serum uric acid (mg/dL) 8.37 ( 2.30 –0.37 ( 0.16 0.025 0.024
p1 from simple regression; p2 from multiple regression; SD = standard deviation; SE = standard error; - = not included.
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although this level was significantly higher than in gout-
free subjects (p < 0.05). The prevalence of HGPRT deficiency
in the population is not accurately known, although an
estimate of the minimum frequency of the disorder in
Canada is 1 in 380,000 births [31]. Puig et al showed that
HGPRT activity in Lesch-Nyhan syndrome or gout patients
with HGPRT variants was about 0–10% of the activity in
normal subjects [30]. Since HGPRT activity was detectable
in all the participants and these activities were normally
distributed about the mean, the evidence provided by this
study that there is no correlation between gout and HGPRT
activity is considerable. This may further suggest that both
gout and uric acid disease are complex diseases affected by
many environmental and genetic factors.
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